ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate | 907572-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate
• 英文别名: ethyl (3R,4S)-4-amino-3-methoxypiperidine-1-carboxylate；ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate；ethyl cis-4-amino-3-methoxy-1-piperidinecarboxylate
• CAS: 907572-18-3
• 化学式: C₉H₁₈N₂O₃
• 分子量: 202.254
• InChiKey: FIIGTSPAEONQHZ-SFYZADRCSA-N

物化性质

• 沸点：
  286.3±40.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate 在 palladium over charcoal titanium(IV) isopropylate 、 sodium hydroxide 、 甲酸铵 、 potassium carbonate 、 异丙醇 、 O,O'-dibenzoyl-L-tartaric acid 、 potassium iodide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 31.0h， 生成 Naronapride
  参考文献：
  名称：

  WO2007/149929

  摘要：

  公开号：
• 作为产物：
  描述：

  3-羟基-4,4-二甲氧基-1-哌啶羧酸乙酯 在 盐酸 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 甲酸铵 、 三乙酰氧基硼氢化钠 、 sodium hydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 16.75h， 生成 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x

文献信息

• 4-(aroylamino)piperidine-butanimide derivatives
  申请人：Janssen Pharmaceutica

  公开号：US04990521A1

  公开（公告）日：1991-02-05

  A method of treating warm-blooded animals suffering from diarrhea, which method comprises the administration of particular 4-(aroylamino)piperidinebutanamide derivatives and compositions containing the same. Novel 4-(aroylamino)piperidinebutanamide derivatives.

  一种治疗患有腹泻的温血动物的方法，该方法包括给予特定的4-(芳酰氨基)哌啶丁酰胺衍生物和包含相同成分的制剂。新型的4-(芳酰氨基)哌啶丁酰胺衍生物。
• Dimethylbenzofuran and dimethylbenzopyran derivatives and their use as
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05674868A1

  公开（公告）日：1997-10-07

  Method of treating 5-HT.sub.3 -mediated disorders, which comprises systemic administration of an effective amount of a compound of formula (I) ##STR1## the pharmaceutically acceptable acid addition salt forms and the stereochemically isomeric forms thereof, wherein R.sup.1 and R.sup.2 represent hydrogen, or R.sup.1 and R.sup.2 taken together form a bivalent radical of formula --CH.dbd.CH--CH.dbd.CH-- (a), --CH.dbd.C(Cl)--CH.dbd.CH-- (b) or --CH.dbd.CH--C(Cl).dbd.CH-- (c); n represents 2, 3 or 4; R.sup.3 represents hydrogen or methoxy; m represents 1 or 2; R.sup.4 represents hydrogen, amino or C.sub.1-3 -alkylcarbonylamino; and R.sup.5 represents hydrogen or halo; novel compounds; compositions; processes for preparing novel compounds and intermediates.

  治疗5-HT.sub.3介导的疾病的方法，包括系统给药有效量的式(I)化合物 ##STR1## 其药学上可接受的酸加成盐形式及其立体化学异构体形式，其中R.sup.1和R.sup.2代表氢，或者R.sup.1和R.sup.2一起形成式--CH.dbd.CH--CH.dbd.CH-- (a)、--CH.dbd.C(Cl)--CH.dbd.CH-- (b)或--CH.dbd.CH--C(Cl).dbd.CH-- (c)的二价基团；n代表2、3或4；R.sup.3代表氢或甲氧基；m代表1或2；R.sup.4代表氢、氨基或C.sub.1-3 -烷基羰基氨基；R.sup.5代表氢或卤素；新化合物；组合物；制备新化合物及其中间体的方法。
• Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04962115A1

  公开（公告）日：1990-10-09

  Novel N-(3-hydroxy-4-piperidinyl)benzamides and derivatives thereof, said compounds being useful as stimulators of the motility of the gastro-intestinal system.

  新型N-(3-羟基-4-哌啶基)苯甲酰胺及其衍生物，所述化合物可用作促进胃肠系统运动的刺激剂。
• [EN] 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS D'ACIDE 2-(PIPÉRIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIQUE CONTRE LES INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2010067125A1

  公开（公告）日：2010-06-17

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  公式（I）的化合物及其药用盐已被描述。还描述了它们的制备过程、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• PIPERDINE COMPOUNDS AND USES THEREOF-911
  申请人：Basarab Gregory

  公开号：US20080312255A1

  公开（公告）日：2008-12-18

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  描述了化合物的公式（I）及其药用盐。还描述了它们的制备过程、含有它们的药物组合物、作为药物的用途以及在治疗细菌感染中的用途。